Ruxolitinib Phosphate

Acute Myeloid Leukemia

City of Hope Medical CenterPhase 2Active

B

56/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 55/ 100
Competitive Position: 59/ 100

Competitive context

684 Active assets in the Acute Myeloid Leukemia cohort.

Asset / Sponsor	Phase	Rating
Gemtuzumab M.D. Anderson Cancer Center	Phase 4	A
Cytosin-Arabinosid Institute of Hematology & Blood Diseases Hospital, China	Phase 3	BBB
AMSACRINE University Hospital, Toulouse	Phase 4	BBB
(+)-VINCRISTINE Janssen Research & Development, LLC	Phase 3	BBB
Posaconazole AstraZeneca	Phase 4	BBB

View all 50 →

Same molecule, other indications

Ruxolitinib Phosphate is also rated in:

mature T-cell and NK-cell non-Hodgkin lymphomaDormant

BB

Indicative ·

64 / 100

myelodysplastic/myeloproliferative neoplasmDormant

B

Indicative ·

59 / 100

myelodysplastic syndromeDormant

CCC

Indicative ·

55 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.